Charles Ryan invites Rahul Aggarwal to discuss treatment-emergent small-cell neuroendocrine prostate cancer, an area not well characterized in the era of modern androgen receptor (AR)-targeting therapy.  

This study was funded by Stand Up to Cancer and the Prostate Cancer Foundation. Patients with metastatic castration-resistant prostate cancer were enrolled in which metastatic tumor biopsies were performed to understand the patterns of resistance beyond first or second-generation hormonal agents.